focus -WSS

focus

author：leisure time 2025-09-06 02:04:55 - browse：53278

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： After traumatic brain injury, life support decisions can use more time

focus

WSS

Cue Health's Covid

How many hemophilia patients actually want gene therapy?

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Close Medicare's dangerous gaps in addiction treatment coverage

Boston's new lab space is opening empty

Amid AI frenzy, a top HHS official's quest to create safeguards

explore

focus

explore

In age of alternative facts, a scholarly course on calling out crap

Why rehabilitation engineers need to center patients in their research

Medicare proposal to cover medical devices draws a mixed reaction

FDA advisers back CAR

Guidelines to prevent youth baseball injuries need more muscle

Close Medicare's dangerous gaps in addiction treatment coverage

At least 13 dead in Texas as scorching temps continue

John Green on his newest strategy for fighting tuberculosis

Medicare details structure of new drug price negotiation program

Close Medicare's dangerous gaps in addiction treatment coverage

focus

FDA advisers back CAR

FTC falls short on scrutinizing hospital mergers, study says

How many hemophilia patients actually want gene therapy?

Why depression after traumatic brain injury is distinct

Amid AI frenzy, a top HHS official's quest to create safeguards

UCLA team creates talking throat patch for voice disorders

focus

Wikipedia

focus

Wikipedia